Genetic influence on early onset Alzeimer's disease;Influência genética sobre a doença de Alzheimer de início precoce

Revista de Psiquiatria Clinica

Volumn 36, Issue 1, 2009, Pages 25-30

  Lucatelli, Juliana Faggion ^a   Barros, Alessandra Chiele ^a   Sharbel, Maluf Weidner ^b   De Andrade, Fabiana Michelsen ^c,d  

^a Bacharel em Biomedicina ^*

^b Licenciado em Ciencias Biologicas mestre   (Italy)

^c Licenciada em Ciencias Biologicas   (Italy)

^d UNIVERSIDADE FEEVALE   (Brazil)

Author keywords

Amyloid precursor protein; Apolipoprotein E; Early onset Alzheimer's disease; Presenilins 1 and 2; TAU protein.

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PRESENILIN; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; EARLY ONSET ALZHEIMER DISEASE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC SCREENING; HUMAN;

EID: 66249140620     PISSN: 01016083     EISSN: 1806938X     Source Type: Journal    
DOI: 10.1590/s0101-60832009000100004     Document Type: Article

References (56)

1. MinistÉrio da SaÚde. Indicadores demogrÁficos. Índice de envelheci- mento. IDB 2005 Brasil - [acessado em 19 mar 2007a]. DisponÍvel em: http://tabnet.datasus.gov.br/cgi/idb2005/a15uf.htm
2. MinistÉrio da SaÚde. Indicadores demogrÁficos. EsperanÇa de vida aos 60 anos de idade. IDB 2005 Brasil - [acessado em 19 mar 2007b]. DisponÍvel em: http://tabnet.datasus.gov.br/cgi/idb2005/ a12t.htm
3. Rocchi A, Pellegrini S, Siciliano G, Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull. 2003; 61: 1-24.
4. Strachan T, Read AP. Human molecular genetics. 3.ed. New York: Garland Science; 2004.
5. Samaia HOB, Filho HPV. Aspectos genÉticos da doenÇa de Alzheimer. Rev Psiq Clin. 2002. 27 mar/abr - [acessado 11 abr 2007]. DisponÍvel em: http://www.hcnet.usp.br/ipq/revista/r27(2)/art104.htm
6. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron. 2001; 32: 181-4.
7. Holmes C. Genotype and phenotype in Alzheimer's disease. Br J Psy- chiatry. 2002; 180: 131-4.
8. Rogaeva E. The solved and unsolved mysteries of the genetics of early- onset Alzheimer's disease. Neuromol Med. 2002; 2: 1-10.
9. Mahley RW, Rall S Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000; 1: 507-37.
10. Rall SC Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 1982; 257: 4171-8.
11. Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein hetero- geneity: cysteinearginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981; 256: 9077-83.
12. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi R. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007; 39: 17-23.
13. Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Stopford C, et al. Apolipoprotein E epsilon4 allele frequency and age at onset of Alzheimer's disease. Dement Geriatr Cogn Disord. 2007; 23: 60-6.
14. Almeida OP. Biologia molecular da doenÇa de Alzheimer: uma luz no fim do tÚnel? Rev Ass Med Brasil. 1997; 43: 77-81.
15. Selkoe DJ. Presenilin, Notch, and the genesis and treatment of Al- zheimer's disease. Proc Natl Acad Sci USA. 2001; 98: 11039-41.
16. Fridman C, Gregorio SP, Neto ED, Ojopi EPB. AlteraÇões genÉticas na doenÇa de Alzheimer. Rev Psiq Clin. 2004; 31: 19-25.
17. Gandy S. The role of cerebral amyloid accumulation in common forms of Alzheimer disease. J Clin Invest. 2005; 115: 1121-9.
18. St George-Hyslop P, Mclachlan DC, Tuda T, Rogaev E, Karlinsky H, Lippa C, et al. Alzheimer's disease and possible gene interaction. Science. 1994;263:537.
19. Theuns J, Marjaux E, Vandenbulcke M, Van Laere K, Kumar-Singh S, Bormans G, et al. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum Mut. 2006; 27: 888-96.
20. NCBI. National Center for Biotechnology Information. SNP - Single Nu- cleotide Polymorphism. [acessado em 8 ago 2007a]. DisponÍvel em: http://www.ncbi.nlm.nih.gov/SNP/snp-ref.cgi?locusId=351&chooseRs=all
21. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349: 704-6.
22. Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem. 2003; 84: 1215-36.
23. Wakutani Y, Watanabe K, Adachi Y, Wada-Isoe K, Urakami K, Ninomiya H, et al. Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004; 75: 1039-42.
24. Mullan M, Craford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus for -amyloid. Nat Genet. 1992; 1: 345-7.
25. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The «Arctic» APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001; 4: 887-93.
26. Theuns J, Broeckhoven CV. Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility. Hum Mol Genet. 2000; 9: 2383-94.
27. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995; 375: 754-60.
28. Hutton M, Busfield F, Wragg M, Crook R, Perez-Tur J, Clark RF, et al. Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease. Neuroreport. 1996, 7:801-5.
29. Bird TD. Enfermedad de Alzheimer y otras demenciais. In: Fauce AS, Braunwald EI, Wilson JB, Martin JB, Kasper DL, Hanser SL, et al. Principios de Medicina Interna. 14.ed. Madrid: McGraw-Hill Inter- americana, 1998.
30. Tamaoka A, Fraser PE, Ishii K, Sahara N, Ozawak K, Ikeda M, et al. Amyloid-betaprotein isoforms in brain of subjects with PS1-linked, beta APP-linked and sporadic Alzheimer disease. Brain Rev Mol Brain Res. 1998; 56: 178-85.
31. Shepherd CE, Gregory GC, Vickers JC, Halliday GM. Novel «»inflamma- tory plaque'» pathology in presenilin-1 Alzheimer's disease. Neuropathol Appl Neurobiol. 2005; 31: 503-11.
32. Perez-Tur J. La genetica y la enfermedad de Alzheimer. Rev Neurol. 2000; 30: 161-9.
33. Ghidoni R, Paterlini A, Benussi L, Binetti G. Presenilin 2 is secreted in mouse primary neurons: a release enhanced by apoptosis. Mech Ageing Dev. 2007; 128: 350-3.
34. NCBI. National Center for Biotechnology Information. SNP - Single Nu- cleotide Polymorphism - [acessado em 8 ago 2007b]. DisponÍvel em: http://www.ncbi.nlm.nih.gov/SNP/snp-ref.cgi?locusId=5663&chooseRs=all
35. NCBI. National Center for Biotechnology Information. SNP - Single Nucle- otide Polymorphism - [acessado em 8 ago 2007c]. DisponÍvel em: http://www.ncbi.nlm.nih.gov/SNP/snp-ref.cgi?locusId=5664&chooseRs=all
36. NCBI. National Center for Biotechnology Information. OMIM - Online Medline Inheritance in Man. Johns Hopkins University - [acessado em 8 ago 2007d]. DisponÍvel em: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi? id=104311
37. Kowalska A, Wender M, Florczar D, Pruchinik-Wolinska D, Modesto- wicz R, Szczech J, et al. Molecular genetics of Alzheimer's disease: Presenilin 1 gene analysis in a cohort of patients fron the Pozna region. J Appl Genet. 2003; 44: 231-4.
38. Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on A-beta(42) production. Proc Natl Acad Sci USA. 2002; 99: 8025-30.
39. Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997; 277: 793-9.
40. Rippon GA, Crook R, Baker M, Halvorsen E, Chin S, Hutton M, et al. Presenilin 1 mutation in an African American family presenting with atypical Alzheimer dementia. Arch Neurol. 2003; 60: 884-8.
41. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, et al. Endoproteolysis of presenilin 1 and accumulation of processed deriva- tives in vivo. Neuron. 1996; 17: 181-90.
42. Verkkoniemi A, Somer M, Rinne JO, Myllykangas L, Crook R, Hardy J, et al. Variant Alzheimer's disease with spastic paraparesis: clinical characterization. Neurology. 2000; 54: 1103-9.
43. Smith MJ, Kwok JBJ, McLean CA, Kril JJ, Broe GA, Nicholson GA, et al. Variable phenotype of Alzheimer's disease with spastic paraparesis. Ann Neurol. 2001; 49: 125-9.
44. Theuns J, Del-Favero J, Dermaut B, Van Duijin CM, Backhovens H, Van Den Broeck MV, et al. Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer's disease and variable expression. Hum Mol Genet. 2000b; 9: 325-31.
45. Lambert JC, Mann DM, Harris JM, Chartier-Harlin MC, Cumming A, Coates J, et al. The -48C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain. J Med Genet. 2001; 38: 353-55.
46. Tomita T, Maruyma K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA. 1997; 94: 2025-30.
47. Marambaud P, Alves da Costa C, Ancolio K, Checler F. Alzheimer's disease-linked mutation of presenilin 2 (N141I-PS2) drastically lowers APP-alpha secretion: control by the proteasome. Biochem Biophys Res Commun. 1998; 252: 134-8.
48. Wijsman EM, Daw EW, Yu X, Steinbart EJ, Nochlin D, Bird TD, et al. APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am J Med Genet B Neuropsychiat Genet. 2005; 132: 14-20.
49. Frigerio SC, Piscopo P, Calabrese E, Crestini A, Campeggi LM, Civita di Fava R, et al. PEN-2 gene mutation in a familial Alzheimer's disease case. J Neurol. 2005; 252: 1033-6.
50. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995; 376: 775-8.
51. Binetti G, Signorini S, Squitti R, Alberici A, Benussi L, Cassetta E, et al. Atypical dementia associated with a novel presenilin-2 mutation. Ann Neurol. 2003; 54: 832-6.
52. MenÉndez SG, Perez NP, Rodriguez JJL. Peptido beta amiloide, proteina Tau y enfermedad de Alzheimer. Trabajos de revision. Rev Cubana Invest Biomed. 2002; 21: 253-61.
53. NCBI. National Center for Biotechnology Information. SNP - Single Nucleotide Polymorphism - [acessado em 8 ago 2007c]. DisponÍvel em: http://www.ncbi.nlm.nih.gov/SNP/snp-ref.cgi? locusId=4137&chooseRs=all
54. Connell JW, Gibb GM, Betts JC, Blackstock WP, Gallo J-M, Lovestone S, et al. Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3-beta identified by mass spectrom- etry demonstrate certain mutations exert long-range conformational changes. FEBS Lett. 2001; 493: 40-4.
55. Rademakers R, Dermaut B, Peeters K, Cruts M, Heutink P, Goate A, et al. Tau (MAPT) mutation arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. Hum Mutat. 2003; 22: 409-11. 56 Tatebayashi Y, Miyasaka T, Chui D-H, Akagi T, Mishima K, Iwasaki K, et al. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci USA. 2002; 99: 13896-901.
56. Saito Y, Geyer A, Sasaki R, Kuzuhara S, Nanba E, Miyasaka T, et al. Early-onset, rapidly progressive familial tauopathy with R406W muta- tion. Neurology. 2002; 58: 811-3.